Key facts
- It has raised $48.9M; the latest was Later Stage VC in Feb 2026.
- Notable investors include Tech Incubator Program for Startup, KB Investment, IMM Investment, Shinhan Venture Investment, Kiwoom Investment — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Spark Biopharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Spark Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Spark Biopharma
Operator of a drug development company intended to focus on the development of small-molecule therapeutics through the integration of biology. The company's therapeutic drug is produced by the compound library and bio probe developed with domestic original technology, it is developing new drug candidates by image-based screening technology using a fluorescent skeleton probe and the target protein identification technology, enabling the medical industry to get therapeutic candidates for cardiovascular and other metabolic diseases.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2016
- Employees
- 30
- Website
- sparkbiopharma.com/
- Ownership
- Privately Held (backing)
Spark Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Spark Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Spark Biopharma in its N-PORT filings yet. We sweep new filings monthly.